Intravenous immunoglobulin in children with streptococcal toxic shock syndrome

Clinical Infectious Diseases

Volumn 49, Issue 9, 2009, Pages 1369-1376

  Shah, Samir S ^a,b   Hall, Matthew ^d   Srivastava, Raj ^e,f   Subramony, Anupama ^g,h   Levin, James E ^c  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^d Child Health Corporation of America   (United States)

^e UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^f PRIMARY CHILDREN'S MEDICAL CENTER   (United States)

^g NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^h NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; HYDROCORTISONE; IMMUNOGLOBULIN; METHYLPREDNISOLONE;

ARTICLE; CHILD; CONTROLLED STUDY; DRUG COST; FEMALE; GROUP A STREPTOCOCCAL INFECTION; HOSPITAL COST; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; SCHOOL CHILD; SCORING SYSTEM; TOXIC SHOCK SYNDROME;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; INFANT; MALE; RETROSPECTIVE STUDIES; SHOCK, SEPTIC; STREPTOCOCCAL INFECTIONS; TREATMENT OUTCOME;

EID: 72849139516     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/606048     Document Type: Article

References (37)

1. Davies HD, McGeer A, Schwartz B, et al; Ontario Group A Streptococcal Study Group. Invasive group A streptococcal infections in Ontario, Canada. N Engl J Med 1996; 335:547-554
2. Lamagni TL, Darenberg J, Luca-Harari B, et al. Epidemiology of severe Streptococcus pyogenes disease in Europe. J Clin Microbiol 2008; 46:2359-2367
3. Demers B, Simor AE, Vellend H, et al. Severe invasive group A streptococcal infections in Ontario, Canada: 1987-1991. Clin Infect Dis 1993; 16:792-800; discussion 1-2.
4. Fleischer B, Gerardy-Schahn R, Metzroth B, Carrel S, Gerlach D, Kohler W. An evolutionary conserved mechanism of T cell activation by microbial toxins: evidence for different affinities of T cell receptor-toxin interaction. J Immunol 1991; 146:11-7
5. Basma H, Norrby-Teglund A, McGeer A, et al. Opsonic antibodies to the surface M protein of group A streptococci in pooled normal immunoglobulins (IVIG): potential impact on the clinical efficacy of IVIG therapy for severe invasive group A streptococcal infections. Infect Immun 1998; 66:2279-2283 (Pubitemid 28194131)
6. Eriksson BK, Andersson J, Holm SE, Norgren M. Invasive group A streptococcal infections: T1M1 isolates expressing pyrogenic exotoxins A and B in combination with selective lack of toxin-neutralizing antibodies are associated with increased risk of streptococcal toxic shock syndrome. J Infect Dis 1999; 180:410-418 (Pubitemid 30256323) (Pubitemid 30256323)
7. Norrby-Teglund A, Pauksens K, Holm SE, Norgren M. Relation between low capacity of human sera to inhibit streptococcal mitogens and serious manifestation of disease. J Infect Dis 1994; 170:585-591 (Pubitemid 24262259)
8. Holm SE, Norrby A, Bergholm AM, Norgren M. Aspects of pathogenesis of serious group A streptococcal infections in Sweden, 1988-1989. J Infect Dis 1992; 166:31-37
9. Norrby-Teglund A, Kaul R, Low DE, et al. Plasma from patients with severe invasive group A streptococcal infections treated with normal polyspecific IgG inhibits streptococcal superantigen-induced T cell proliferation and cytokine production. J Immunol 1996; 156:3057-3064 (Pubitemid 126660657)
10. Sriskandan S, Ferguson M, Elliot V, Faulkner L, Cohen J. Human intravenous immunoglobulin for experimental streptococcal toxic shock: bacterial clearance and modulation of inflammation. J Antimicrob Chemother 2006; 58:117-124 (Pubitemid 44294995) (Pubitemid 44294995)
11. Kaul R, McGeer A, Norrby-Teglund A, et al; The Canadian Streptococcal Study Group. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome: a comparative observational study. Clin Infect Dis 1999; 28:800-807
12. Darenberg J, Ihendyane N, Sjolin J, et al. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2003; 37: 333-340 (Pubitemid 36976489) (Pubitemid 36976489)
13. Davies HD, Matlow A, Scriver SR, et al. Apparent lower rates of streptococcal toxic shock syndrome and lower mortality in children with invasive group A streptococcal infections compared with adults. Pediatr Infect Dis J 1994; 13:49-56. (Pubitemid 24039295)
14. OBrien KL, Beall B, Barrett NL, et al. Epidemiology of invasive group a streptococcus disease in the United States, 1995-1999. Clin Infect Dis 2002; 35:268-276
15. Chuang YY, Huang YC, Lin TY. Toxic shock syndrome in children: epidemiology, pathogenesis, and management. Paediatr Drugs 2005; 7:11-25. (Pubitemid 40444226) (Pubitemid 40444226)
16. Laupland KB, Davies HD, Low DE, Schwartz B, Green K, McGeer A; Ontario Group A Streptococcal Study Group. Invasive group A streptococcal disease in children and association with varicella-zoster virus infection. Pediatrics 2000; 105:E60.
17. Burnett AM, Domachowske JB. Therapeutic considerations for children with invasive group a streptococcal infections: a case series report and review of the literature. Clin Pediatr (Phila) 2007; 46:550-555
18. Cawley MJ, Briggs M, Haith LR Jr, et al. Intravenous immunoglobulin as adjunctive treatment for streptococcal toxic shock syndrome associated with necrotizing fasciitis: case report and review. Pharmacotherapy 1999; 19:1094-1098 (Pubitemid 29413649) (Pubitemid 29413649)
19. Nadal D, Lauener RP, Braegger CP, et al. T cell activation and cytokine release in streptococcal toxic shock-like syndrome. J Pediatr 1993; 122: 727-729 (Pubitemid 23134959)
20. Powell C, Bubb S, Clark J. Toxic shock syndrome in a neonate. Pediatr Infect Dis J 2007; 26:759-760
21. Feudtner C, Hays RM, Haynes G, Geyer JR, Neff JM, Koepsell TD. Deaths attributed to pediatric complex chronic conditions: national trends and implications for supportive care services. Pediatrics 2001; 107:E99.
22. Stein CM. Estimation of the mean of a multivariate normal distribution. Ann Stat 1981; 9:1135-1151
23. Braitman LE, Rosenbaum PR. Rare outcomes, common treatments: analytic strategies using propensity scores. Ann Intern Med 2002; 137: 693-695
24. Harrell FE, Jr., Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15:361-387
25. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol 1996; 49:1373-1379 (Pubitemid 27028925)
26. Glynn RJ, Schneeweiss S, Sturmer T. Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol 2006; 98:253-259
27. Gu XS, Rosenbaum PR. Comparison of multivariate matching methods: structures, distances and algorithms. J Computat Graph Stat 1993; 2:405-420
28. Sturmer T, Joshi M, Glynn RJ, Avorn J, Rothman KJ, Schneeweiss S. A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol 2006; 59:437-447 (Pubitemid 44316748) (Pubitemid 44316748)
29. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70:41-55.
30. Weitzen S, Lapane KL, Toledano AY, Hume AL, Mor V. Principles for modeling propensity scores in medical research: a systematic literature review. Pharmacoepidemiol Drug Saf 2004; 13:841-853 (Pubitemid 40003819) (Pubitemid 40003819)
31. Rosenbaum PR, Rubin DB. Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Stat 1985; 39:33-38
32. Bonferroni CE. Il calcolo delle assicurazioni su gruppi di teste. In: Studi in Onore del Professore Salvatore Ortu Carboni. Rome, Italy: 1935:13-60.
33. Norrby-Teglund A, Kotb M. Host-microbe interactions in the pathogenesis of invasive group A streptococcal infections. J Med Microbiol 2000; 49:849-852 (Pubitemid 30749033)
34. Kotb M. Bacterial pyrogenic exotoxins as superantigens. Clin Microbiol Rev 1995; 8:411-426
35. The Working Group on Severe Streptococcal Infections. Defining the group A streptococcal toxic shock syndrome: rationale and consensus definition. JAMA 1993; 269:390-391
36. Norrby-Teglund A, Basma H, Andersson J, McGeer A, Low DE, Kotb M. Varying titers of neutralizing antibodies to streptococcal superantigens in different preparations of normal polyspecific immunoglobulin G: implications for therapeutic efficacy. Clin Infect Dis 1998; 26:631-638 (Pubitemid 28155011)
37. Schrage B, Duan G, Yang LP, Fraser JD, Proft T. Different preparations of intravenous immunoglobulin vary in their efficacy to neutralize streptococcal superantigens: implications for treatment of streptococcal toxic shock syndrome. Clin Infect Dis 2006; 43:743-746 (Pubitemid 44330738) (Pubitemid 44330738)